GSK plc
GSK · NYSE
10/28/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.98 | 0.03 | -0.04 |
| FCF Yield | 2.95% | 2.57% | 1.14% | 2.17% |
| EV / EBITDA | 32.01 | 23.43 | 25.65 | 61.16 |
| Quality | ||||
| ROIC | 3.92% | 3.15% | 3.45% | 1.54% |
| Gross Margin | 73.58% | 72.89% | 74.23% | 68.47% |
| Cash Conversion Ratio | 1.12 | 1.27 | 0.65 | 4.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.75% | 2.54% | 2.73% | 2.28% |
| Free Cash Flow Growth | 77.66% | 109.90% | -41.62% | -8.99% |
| Safety | ||||
| Net Debt / EBITDA | 5.79 | 5.84 | 5.83 | 11.88 |
| Interest Coverage | 15.53 | 10.99 | 13.68 | 4.83 |
| Efficiency | ||||
| Inventory Turnover | 0.27 | 0.26 | 0.25 | 0.45 |
| Cash Conversion Cycle | -395.10 | -379.47 | -432.76 | 144.14 |